To date, a majority of the reported CART19 trials include the anti-CD19 scFv extracted from FMC63, such as both the FDA-approved CARs Kymriah and Yescarta. Although the therapeutic results for ...

CAR T cell therapy revolutionizes oncology by using engineered T cells to target and eliminate cancer cells, improving outcomes in hematological malignancies.